| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Toshiyuki Sakaeda | |
| Kaori Kadoyama | |||
| Yasushi Okuno | |||
| Akiko Tamon | |||
| P2860 | cites work | On the relative safety of parenteral iron formulations | Q28262418 |
| Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system | Q28478481 | ||
| Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach | Q28481469 | ||
| A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database | Q30623879 | ||
| The need for definitions in pharmacovigilance | Q81293668 | ||
| Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use | Q81914074 | ||
| Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase | Q83437449 | ||
| Making a difference | Q83622807 | ||
| The FDA drug safety surveillance program: adverse event reporting trends | Q83737784 | ||
| First, catch your signal! | Q83929035 | ||
| Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still low | Q84080779 | ||
| Caution in making inferences from FDA's Adverse Event Reporting System | Q84174532 | ||
| More eyeballs on AERS | Q84197892 | ||
| A pre-marketing ALT signal predicts post-marketing liver safety | Q84300090 | ||
| Data quality management in pharmacovigilance | Q30959027 | ||
| Perspectives on the use of data mining in pharmaco-vigilance | Q33225414 | ||
| An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system | Q33372417 | ||
| Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations | Q33397057 | ||
| Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations | Q33398998 | ||
| Decision support methods for the detection of adverse events in post-marketing data | Q33404940 | ||
| Influence of the MedDRA hierarchy on pharmacovigilance data mining results | Q33410935 | ||
| Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System | Q33411472 | ||
| Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria | Q33422275 | ||
| Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). | Q33428656 | ||
| Systematic investigation of time windows for adverse event data mining for recently approved drugs | Q33447128 | ||
| Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles | Q33524879 | ||
| Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System | Q33542747 | ||
| Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. | Q33911016 | ||
| Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database | Q33959722 | ||
| Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. | Q34039745 | ||
| The role of databases in drug postmarketing surveillance | Q34110387 | ||
| Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports | Q34112790 | ||
| Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists | Q34173180 | ||
| Mining multi-item drug adverse effect associations in spontaneous reporting systems | Q34259525 | ||
| Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system | Q34300253 | ||
| Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System | Q34320987 | ||
| Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. | Q34364050 | ||
| Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions | Q34429480 | ||
| Evidence-based management of statin myopathy. | Q34621494 | ||
| A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. | Q34629802 | ||
| Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer | Q34662657 | ||
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 | ||
| Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database | Q35629751 | ||
| When to publish measures of disproportionality derived from spontaneous reporting databases? | Q35629757 | ||
| Biclustering of adverse drug events in the FDA's spontaneous reporting system. | Q35764731 | ||
| The reporting odds ratio and its advantages over the proportional reporting ratio | Q35865910 | ||
| Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database | Q36088026 | ||
| Under-reporting of adverse drug reactions : a systematic review | Q36475336 | ||
| Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods | Q36655440 | ||
| Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide | Q36711090 | ||
| Novel statistical tools for monitoring the safety of marketed drugs | Q36835511 | ||
| Database size and power to detect safety signals in pharmacovigilance | Q36984256 | ||
| Pharmacovigilance: methods, recent developments and future perspectives | Q37181786 | ||
| Determinants of under-reporting of adverse drug reactions: a systematic review. | Q37365382 | ||
| Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions | Q37399075 | ||
| Quantitative signal detection using spontaneous ADR reporting | Q37439662 | ||
| Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database | Q37986306 | ||
| Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). | Q39581963 | ||
| Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications | Q39679666 | ||
| Drug Fever: a descriptive cohort study from the French national pharmacovigilance database. | Q40279591 | ||
| Drug-induced pancreatitis: lessons in data mining | Q42759432 | ||
| Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias | Q43761720 | ||
| Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration | Q44955650 | ||
| Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase | Q44997280 | ||
| Rosuvastatin and the statin wars--the way to peace | Q45175615 | ||
| Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal | Q45740000 | ||
| Comparison of rates of reported adverse events associated with i.v. iron products in the United States | Q45792335 | ||
| Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. | Q45937737 | ||
| Update on adverse drug events associated with parenteral iron | Q46212164 | ||
| Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants | Q46239220 | ||
| Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy | Q46332848 | ||
| Cetuximab infusion reactions: French pharmacovigilance database analysis | Q46370825 | ||
| Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect | Q46476759 | ||
| The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. | Q46493432 | ||
| Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? | Q46569978 | ||
| Use of parenteral iron products and serious anaphylactic-type reactions | Q46599031 | ||
| Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database | Q46643138 | ||
| [French pharmacovigilance database system: examples of utilisation]. | Q51017833 | ||
| An experimental investigation of masking in the US FDA adverse event reporting system database. | Q51637379 | ||
| An evaluation of three signal-detection algorithms using a highly inclusive reference event database. | Q51828330 | ||
| Reports of hyperkalemia after publication of RALES--a pharmacovigilance study. | Q51938827 | ||
| A Bayesian neural network method for adverse drug reaction signal generation. | Q52238255 | ||
| OpenVigil--free eyeballs on AERS pharmacovigilance data. | Q53667609 | ||
| The statin wars: why AstraZeneca must retreat | Q55952455 | ||
| A potential competition bias in the detection of safety signals from spontaneous reporting databases | Q57521230 | ||
| Examination of pharmacists’ intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior | Q59207906 | ||
| Drug-induced gingival overgrowth: a study in the French Pharmacovigilance Database | Q61314471 | ||
| An Educational Intervention to Improve Physician Reporting of Adverse Drug Reactions | Q61459362 | ||
| The reporting odds ratio versus the proportional reporting ratio:‘deuce’ | Q63865876 | ||
| Practical pharmacovigilance analysis strategies | Q79163239 | ||
| Serious adverse drug events reported to the Food and Drug Administration, 1998-2005 | Q81229276 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | data mining | Q172491 |
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 796-803 | |
| P577 | publication date | 2013-04-25 | |
| P1433 | published in | International Journal of Medical Sciences | Q10927439 |
| P1476 | title | Data mining of the public version of the FDA Adverse Event Reporting System | |
| P478 | volume | 10 |
| Q37348321 | A CTD-Pfizer collaboration: manual curation of 88,000 scientific articles text mined for drug-disease and drug-phenotype interactions. |
| Q57412712 | A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports |
| Q39434182 | A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. |
| Q92888597 | A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use |
| Q36909828 | A survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms |
| Q92664267 | AI in Health: State of the Art, Challenges, and Future Directions |
| Q28551402 | Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada |
| Q38673424 | An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System |
| Q52665543 | An evaluation of the Manufacturer And User Facility Device Experience database that inspired the United States Food and Drug Administration's Reclassification of transvaginal mesh. |
| Q57292050 | An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs |
| Q37024628 | Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database. |
| Q47267683 | Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database |
| Q91989799 | Analyzing Medication Error Reports in Clinical Settings: An Automated Pipeline Approach |
| Q90645696 | Applications of the microphysiology systems database for experimental ADME-Tox and disease models |
| Q89811151 | Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews |
| Q28554297 | Assessment of the Risk of Suicide-Related Events Induced by Concomitant Use of Antidepressants in Cases of Smoking Cessation Treatment with Varenicline and Assessment of Latent Risk by the Use of Varenicline |
| Q91686431 | Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system |
| Q28602965 | Association Patterns in Open Data to Explore Ciprofloxacin Adverse Events |
| Q31144205 | Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases |
| Q40220701 | Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system |
| Q90344371 | Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach |
| Q35069176 | Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database |
| Q30803396 | Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database |
| Q30975567 | Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats. |
| Q47634136 | Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data. |
| Q89172390 | Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database |
| Q50221688 | Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications |
| Q40218182 | Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). |
| Q30884142 | Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System |
| Q88359245 | Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients |
| Q55009284 | Characterizing drug-related adverse events by joint analysis of biomedical and genomic data: A case study of drug-induced pulmonary fibrosis. |
| Q95259264 | Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program |
| Q30790443 | Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms |
| Q47847824 | Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). |
| Q41945537 | Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. |
| Q28651547 | Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks |
| Q31114073 | Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data |
| Q64914429 | Detecting Signals of Dietary Supplement Adverse Events from the CFSAN Adverse Event Reporting System (CAERS). |
| Q89313072 | Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study |
| Q39216921 | Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system |
| Q38976138 | Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events |
| Q38371804 | Discovering associations between adverse drug events using pattern structures and ontologies. |
| Q64068821 | Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity |
| Q39648159 | EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication |
| Q38817615 | Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). |
| Q45992660 | Evaluating Casama: Contextualized semantic maps for summarization of lung cancer studies. |
| Q35475000 | Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age |
| Q35559500 | Exploring adverse drug events at the class level |
| Q28551405 | Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions |
| Q91635987 | Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy |
| Q33746359 | HSP105 prevents depression-like behavior by increasing hippocampal brain-derived neurotrophic factor levels in mice |
| Q38682276 | In silico Prediction of Drug-induced Liver Injury Based on Adverse Drug Reaction Reports |
| Q90373768 | In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices |
| Q91260381 | Integrative analysis of clinical and bioinformatics databases to identify anticancer properties of digoxin |
| Q31040399 | Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases |
| Q58886440 | Knowledge Discovery and Visualization of Clusters for Erythromycin Related Adverse Events in the FDA Drug Adverse Event Reporting System |
| Q30841748 | Lean Big Data integration in systems biology and systems pharmacology |
| Q90238734 | Learning predictive models of drug side-effect relationships from distributed representations of literature-derived semantic predications |
| Q50434042 | Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database. |
| Q39845723 | Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project. |
| Q47950620 | Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). |
| Q92064594 | Mining Drugs and Indications for Suicide-Related Adverse Events |
| Q47381084 | Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs |
| Q90712012 | Myelosuppression with Oxazolidinones: Are There Differences? |
| Q41752200 | No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database |
| Q36804419 | Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events |
| Q28548499 | Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project |
| Q40777322 | Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study |
| Q88086293 | Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions |
| Q31097538 | Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism |
| Q91386324 | Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory |
| Q30976077 | Publisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction |
| Q41784210 | Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs |
| Q64910953 | Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis. |
| Q48305786 | Reply to 'Risk of malignancies associated with ustekinumab'. |
| Q58613837 | Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database" |
| Q53614114 | Risk of intraocular hemorrhage with new oral anticoagulants. |
| Q39133567 | Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database |
| Q38570374 | Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective |
| Q55265837 | Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010-2015. |
| Q64276438 | Solr-Plant: efficient extraction of plant names from text |
| Q40897287 | Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants |
| Q58610116 | Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System |
| Q55649893 | Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. |
| Q39956333 | The Risk of Glioblastoma with TNF Inhibitors |
| Q38622261 | The benefits of data mining |
| Q90171418 | The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database |
| Q52361345 | Traditional Chinese medicine pharmacovigilance in signal detection: decision tree-based data classification. |
| Q31063553 | Use of "big data" in drug discovery and clinical trials. |
| Q102144627 | Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk |
| Q48827554 | Use of blood products in patients with anticoagulant-related major bleeding: an analysis of inhospital outcomes |
| Q36056257 | Using Literature-Based Discovery to Explain Adverse Drug Effects |
| Q88628798 | WITHDRAWN: Cognition and Dementia Related Adverse Effects with Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database |
Search more.